LU90426I2 - Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir - Google Patents

Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir

Info

Publication number: LU90426I2
Authority: LU; Luxembourg
Prior art keywords: abacavir; optionally; pharmaceutically acceptable; acceptable salt; derivative including
Prior art date: 1989-12-22

Application number

LU90426C

Other languages

English (en)

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-22

Filing date

1999-08-06

Publication date

1999-10-06

1989-12-22 Priority claimed from US07/455,201 external-priority patent/US5034394A/en

1999-08-06 Application filed by Wellcome Found filed Critical Wellcome Found

1999-10-06 Publication of LU90426I2 publication Critical patent/LU90426I2/fr

Links

229960004748 abacavir Drugs 0.000 title 1
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 title 1
229960000531 abacavir sulfate Drugs 0.000 title 1
WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU90426C 1989-12-22 1999-08-06 Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir LU90426I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/455,201 US5034394A (en)	1988-06-27	1989-12-22	Therapeutic nucleosides

Publications (1)

Publication Number	Publication Date
LU90426I2 true LU90426I2 (fr)	1999-10-06

Family

ID=23807819

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU90426C LU90426I2 (fr)	1989-12-22	1999-08-06	Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir

Country Status (29)

Country	Link
EP (3)	EP0921114A1 (fr)
JP (2)	JPH11158160A (fr)
CN (1)	CN1028106C (fr)
AP (1)	AP196A (fr)
AT (1)	ATE181917T1 (fr)
AU (1)	AU633672B2 (fr)
CA (1)	CA2033044C (fr)
CY (1)	CY2145B1 (fr)
CZ (1)	CZ283481B6 (fr)
DE (2)	DE19975058I1 (fr)
DK (1)	DK0434450T3 (fr)
ES (1)	ES2133138T3 (fr)
FI (1)	FI106461B (fr)
GR (1)	GR3031100T3 (fr)
HU (3)	HU220630B1 (fr)
IE (3)	IE990826A1 (fr)
IL (1)	IL96748A (fr)
LU (1)	LU90426I2 (fr)
MX (1)	MX9203215A (fr)
MY (1)	MY104575A (fr)
NL (1)	NL990028I2 (fr)
NZ (1)	NZ236593A (fr)
PL (1)	PL167097B1 (fr)
PT (1)	PT96321B (fr)
RU (2)	RU2068849C1 (fr)
SG (1)	SG49685A1 (fr)
SK (2)	SK658390A3 (fr)
TW (2)	TW473466B (fr)
ZA (1)	ZA9010365B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT89482B (pt) *	1988-01-20	1994-02-28	Univ Minnesota	Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
CA2001401A1 (fr) *	1988-10-25	1990-04-25	Claude Piantadosi	Derives d'ether ou d'ester lipidique contenant une amine quaternaire et composes therapeutiques
GB9108376D0 (en) *	1991-04-19	1991-06-05	Enzymatix Ltd	Cyclopentenes
GB9204015D0 (en) *	1992-02-25	1992-04-08	Wellcome Found	Therapeutic nucleosides
GB9205071D0 (en) *	1992-03-09	1992-04-22	Wellcome Found	Therapeutic nucleosides
CA2164717C (fr) *	1993-06-10	2009-10-20	Louis S. Kucera	Methode de lutte contre une infection due au virus de l'hepatite b
GB9402161D0 (en)	1994-02-04	1994-03-30	Wellcome Found	Chloropyrimidine intermediates
GB9417249D0 (en) *	1994-08-26	1994-10-19	Wellcome Found	A novel salt
JP4259611B2 (ja)	1994-08-29	2009-04-30	ウェイクフォレストユニバーシティ	ウィルス感染を治療するための脂質アナログ
US7135584B2 (en)	1995-08-07	2006-11-14	Wake Forest University	Lipid analogs for treating viral infections
US5977061A (en) *	1995-04-21	1999-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	N6 - substituted nucleotide analagues and their use
GB9600142D0 (en) *	1996-01-05	1996-03-06	Wellcome Found	Chemical compounds
IL127350A0 (en) *	1996-06-25	1999-10-28	Glaxo Group Ltd	Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
WO1997049411A1 (fr)	1996-06-25	1997-12-31	Glaxo Group Limited	Combinaisons comprenant du vx478, de la zidovudine, du ftc et/ou 3tc pouvant etre utilisees dans le traitement du vih
US5866702A (en) *	1996-08-02	1999-02-02	Cv Therapeutics, Incorporation	Purine inhibitors of cyclin dependent kinase 2
SK285228B6 (sk) *	1997-05-13	2006-09-07	Lonza Ag	Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén
AU769660B2 (en) *	1997-05-17	2004-01-29	Glaxo Group Limited	Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) *	1997-05-17	1997-07-09	Glaxo Group Ltd	A novel salt
GB9721780D0 (en)	1997-10-14	1997-12-10	Glaxo Group Ltd	Process for the synthesis of chloropurine intermediates
AU2702899A (en) *	1997-10-24	1999-05-17	Glaxo Group Limited	Process for preparing a chiral nucleoside analogue
EP1032573A1 (fr) *	1997-11-12	2000-09-06	Glaxo Group Limited	Procede de preparation d'un analogue de nucleoside chiral
CZ298144B6 (cs) *	1997-11-27	2007-07-04	Lonza Ag	Zpusob výroby (1S,4R)- nebo (1R,4S)-4-(2-amino-6-chlor-9-H-purin-9-yl)-2-cyklopenten-1-methanolu
YU44900A (sh)	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
GB9802472D0 (en) *	1998-02-06	1998-04-01	Glaxo Group Ltd	Pharmaceutical compositions
GB9820417D0 (en) *	1998-09-18	1998-11-11	Glaxo Group Ltd	Antiviral combinations
GB9821058D0 (en)	1998-09-28	1998-11-18	Univ Cardiff	Chemical compound
EP1124805B1 (fr) *	1998-10-30	2003-05-21	Lonza AG	Procede de production de 4-[(2',5'- diamino-6'- halopyrimidin- 4'-yl)amino]- cyclopent-2- enylmethanols
US6433170B1 (en)	1998-10-30	2002-08-13	Lonza Group	Method for producing 4-[2',5'-diamino-6'-halopyrimidine-4'-yl)amino]- cyclopent-2-enylmethanols
GB9903091D0 (en) *	1999-02-12	1999-03-31	Glaxo Group Ltd	Therapeutic nucleoside compound
US7026469B2 (en)	2000-10-19	2006-04-11	Wake Forest University School Of Medicine	Compositions and methods of double-targeting virus infections and cancer cells
WO2001042255A1 (fr) *	1999-12-10	2001-06-14	Glaxo Group Limited	DERIVES (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D)&excl; PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL UTILISES COMME ANTIVIRAUX
PE20010915A1 (es) *	1999-12-10	2001-09-29	Glaxo Group Ltd	Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
DE10042655A1 (de)	2000-08-31	2002-03-14	Aventis Pharma Gmbh	Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
US7309696B2 (en)	2000-10-19	2007-12-18	Wake Forest University	Compositions and methods for targeting cancer cells
EP1406911B1 (fr)	2001-06-29	2016-01-06	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Dérivés de 6-[2-(phosphonomethoxy)alkoxy] pyrimidine et leur activité antivirale
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1427849B1 (fr) *	2001-08-21	2013-05-15	VIIV Healthcare UK Limited	Procede de depistage des reactions d'hypersensibilite a des medicaments
US7550261B2 (en)	2001-08-21	2009-06-23	Smithkline Beecham Corporation	Method of screening for drug hypersensitivity reaction
KR100871648B1 (ko)	2001-08-31	2008-12-03	톰슨 라이센싱	조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
US6780635B2 (en)	2001-12-27	2004-08-24	Council Of Scientific And Industrial Research	Process for the preparation of optically active azabicyclo heptanone derivatives
CN1302779C (zh) *	2002-06-27	2007-03-07	美迪维尔公司	含有阿巴卡韦和阿洛夫定的药物制剂及其用途
RU2233842C1 (ru) *	2003-01-13	2004-08-10	Петров Владимир Иванович	Производные пурина, обладающие противовирусной активностью
NZ543864A (en)	2003-06-16	2009-10-30	Leuven K U Res & Dev	Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
GB0320738D0 (en)	2003-09-04	2003-10-08	Glaxo Group Ltd	Novel process
EP1857458A1 (fr) *	2006-05-05	2007-11-21	SOLMAG S.p.A.	Procédé de préparation de l'abacavir
EP1905772A1 (fr) *	2006-09-28	2008-04-02	Esteve Quimica, S.A.	Procédé de préparation de l'abacavir
CA2662586A1 (fr) *	2006-09-28	2008-04-03	Esteve Quimica, S.A.	Procede de preparation d'abacavir
EP1939196A1 (fr) *	2006-12-21	2008-07-02	Esteve Quimica, S.A.	Procédé de préparation d'abacavir
AU2008265397C1 (en)	2007-06-18	2013-08-29	Sunshine Lake Pharma Co., Ltd.	Bromo-phenyl substituted thiazolyl dihydropyrimidines
EP2085397A1 (fr) *	2008-01-21	2009-08-05	Esteve Quimica, S.A.	Forme cristalline d'abacavir
TWI444384B (zh)	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
CA2734454C (fr)	2008-09-09	2016-09-13	Astrazeneca Ab	Procede pour preparer le [1s-[1-alpha,2-alpha,3-beta(1s,2r)-5-beta]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3h-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-h ydroxyethoxy)cyclopentane-1,2-diol et ses intermediaires
AU2012363635B2 (en) *	2012-01-03	2015-07-23	Cellceutix Corporation	Carbocyclic nucleosides and their pharmaceutical use and compositions
WO2014133085A1 (fr)	2013-02-27	2014-09-04	国立大学法人京都大学	Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer
ES2651854T3 (es)	2013-10-03	2018-01-30	Lupin Limited	Clorhidrato de abacavir monohidrato cristalino y procedimiento para su preparación
CN104558035B (zh) *	2013-10-22	2017-12-19	连云港恒运药业有限公司	一种替诺福韦前药的纯化方法
CN104788451A (zh) *	2014-01-21	2015-07-22	浙江九洲药业股份有限公司	一种阿巴卡韦的制备方法
CN109239253B (zh) *	2018-09-21	2021-07-09	江苏威奇达药业有限公司	一种阿巴卡韦的杂质的高效液相检测方法
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT86377B (pt) *	1986-12-24	1990-11-20	Lilly Co Eli	Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
PT89482B (pt) *	1988-01-20	1994-02-28	Univ Minnesota	Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
GB8815265D0 (en) *	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
DE68907013D1 (de) *	1988-10-24	1993-07-15	Wellcome Found	Guaninderivate mit antiviraler wirkung und deren pharmazeutisch vertraegliche salze.
NZ233197A (en) *	1989-04-13	1991-11-26	Richard Thomas Walker	Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US4939252A (en) *	1989-04-20	1990-07-03	Hoffmann-La Roche Inc.	Novel intermediates for the preparation of Carbovir

1990
- 1990-12-20 MY MYPI90002230A patent/MY104575A/en unknown
- 1990-12-21 HU HU9902543A patent/HU220630B1/hu unknown
- 1990-12-21 SG SG1996004082A patent/SG49685A1/en unknown
- 1990-12-21 IL IL9674890A patent/IL96748A/en not_active IP Right Cessation
- 1990-12-21 IE IE19990826A patent/IE990826A1/en unknown
- 1990-12-21 CZ CS906583A patent/CZ283481B6/cs not_active IP Right Cessation
- 1990-12-21 FI FI906367A patent/FI106461B/fi active Protection Beyond IP Right Term
- 1990-12-21 CN CN91100671A patent/CN1028106C/zh not_active Expired - Lifetime
- 1990-12-21 HU HU9902539A patent/HU220067B/hu unknown
- 1990-12-21 EP EP99103526A patent/EP0921114A1/fr not_active Withdrawn
- 1990-12-21 AT AT90314089T patent/ATE181917T1/de active
- 1990-12-21 EP EP90314089A patent/EP0434450B1/fr not_active Expired - Lifetime
- 1990-12-21 AU AU68419/90A patent/AU633672B2/en not_active Expired
- 1990-12-21 DK DK90314089T patent/DK0434450T3/da active
- 1990-12-21 EP EP99103525A patent/EP0921121A1/fr not_active Withdrawn
- 1990-12-21 DE DE1990633197 patent/DE19975058I1/de active Pending
- 1990-12-21 DE DE69033197T patent/DE69033197T2/de not_active Expired - Lifetime
- 1990-12-21 IE IE19990825A patent/IE990825A1/en unknown
- 1990-12-21 HU HU407/90A patent/HU219454B/hu unknown
- 1990-12-21 ZA ZA9010365A patent/ZA9010365B/xx unknown
- 1990-12-21 CA CA002033044A patent/CA2033044C/fr not_active Expired - Lifetime
- 1990-12-21 RU SU904894161A patent/RU2068849C1/ru active
- 1990-12-21 NZ NZ236593A patent/NZ236593A/en unknown
- 1990-12-21 ES ES90314089T patent/ES2133138T3/es not_active Expired - Lifetime
- 1990-12-21 AP APAP/P/1990/000234A patent/AP196A/en active
- 1990-12-21 PT PT96321A patent/PT96321B/pt not_active IP Right Cessation
- 1990-12-21 IE IE465290A patent/IE904652A1/en not_active IP Right Cessation
- 1990-12-21 SK SK6583-90A patent/SK658390A3/sk not_active IP Right Cessation
- 1990-12-21 PL PL90288403A patent/PL167097B1/pl unknown
1991
- 1991-04-09 TW TW088111311A patent/TW473466B/zh not_active IP Right Cessation
- 1991-04-09 TW TW080102699A patent/TW371660B/zh not_active IP Right Cessation
1992
- 1992-06-04 RU SU925011830A patent/RU2091386C1/ru active
- 1992-06-24 MX MX9203215A patent/MX9203215A/es active IP Right Grant
- 1992-08-10 SK SK2470-92A patent/SK280000B6/sk not_active IP Right Cessation
1998
- 1998-09-28 JP JP10273408A patent/JPH11158160A/ja active Pending
1999
- 1999-05-06 JP JP11126185A patent/JPH11343292A/ja active Pending
- 1999-08-06 LU LU90426C patent/LU90426I2/fr unknown
- 1999-08-26 GR GR990402183T patent/GR3031100T3/el unknown
- 1999-09-14 NL NL990028C patent/NL990028I2/nl unknown
- 1999-12-09 CY CY9900044A patent/CY2145B1/xx unknown

Also Published As

Publication number	Publication date
IE990826A1 (en)	2000-12-13
DK0434450T3 (da)	2000-01-31
NZ236593A (en)	1994-01-26
TW473466B (en)	2002-01-21
IE904652A1 (en)	1991-07-17
DE19975058I1 (de)	2007-01-25
FI906367L (fi)	1991-06-23
JPH11158160A (ja)	1999-06-15
HU219454B (hu)	2001-04-28
HU220630B1 (hu)	2002-03-28
PT96321A (pt)	1991-09-30
SK247092A3 (en)	1999-06-11
RU2068849C1 (ru)	1996-11-10
CA2033044C (fr)	1999-07-13
TW371660B (en)	1999-10-11
HK1009600A1 (en)	1999-06-04
DE69033197D1 (de)	1999-08-12
MY104575A (en)	1994-04-30
RU2091386C1 (ru)	1997-09-27
HU9902543D0 (en)	1999-10-28
EP0434450A3 (en)	1992-07-08
DE69033197T2 (de)	1999-10-28
EP0434450A2 (fr)	1991-06-26
IL96748A (en)	1995-07-31
ATE181917T1 (de)	1999-07-15
CZ658390A3 (en)	1997-11-12
CN1028106C (zh)	1995-04-05
ZA9010365B (en)	1992-08-26
CA2033044A1 (fr)	1991-06-23
SK280216B6 (sk)	1999-10-08
AU633672B2 (en)	1993-02-04
AU6841990A (en)	1991-06-27
AP196A (en)	1992-06-30
FI106461B (fi)	2001-02-15
HU9902539D0 (en)	1999-10-28
GR3031100T3 (en)	1999-12-31
NL990028I1 (nl)	1999-11-01
EP0921121A1 (fr)	1999-06-09
SK280000B6 (sk)	1999-06-11
EP0434450B1 (fr)	1999-07-07
SK658390A3 (en)	1999-10-08
HU220067B (hu)	2001-10-28
SG49685A1 (en)	1998-06-15
JPH11343292A (ja)	1999-12-14
EP0921114A1 (fr)	1999-06-09
PL288403A1 (en)	1992-06-26
PL167097B1 (pl)	1995-07-31
CY2145B1 (en)	2002-06-21
HU9008407D0 (en)	1991-07-29
PT96321B (pt)	1998-06-30
FI906367A0 (fi)	1990-12-21
CN1054981A (zh)	1991-10-02
IE990825A1 (en)	2000-12-13
AP9000234A0 (en)	1991-01-31
NL990028I2 (nl)	2000-02-01
ES2133138T3 (es)	1999-09-01
IL96748A0 (en)	1991-09-16
MX9203215A (es)	1992-07-01
CZ283481B6 (cs)	1998-04-15

Publication	Publication Date	Title
LU90426I2 (fr)	1999-10-06	Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU88809I2 (fr)	1997-01-03	Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU88746I2 (fr)	1996-10-04	Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU90593I2 (fr)	2000-08-07	Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU90468I2 (fr)	2000-01-03	Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU88842I2 (fr)	1997-01-27	Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU91372I2 (fr)	2007-12-24	Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU91306I2 (fr)	2007-03-19	Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU91599I2 (fr)	2009-10-19	Lasofoxifene, optionnellement sous forme d'un sel d'addition acide, d'un N-oxyde, d'unester ou d'un sel d'ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
LU91442I2 (fr)	2008-07-21	"Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU91290I2 (fr)	2007-01-22	Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU91027I2 (fr)	2004-04-28	Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable
LU92428I2 (fr)	2014-06-10	Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
LU90097I2 (fr)	1997-07-16	Ropinirole facultativement sous forme de sels pharmaceutiquement acceptables et de préférence le sel hydrochlorique
LU92699I2 (fr)	2015-06-24	Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
IT1240360B (it)	1993-12-10	Uso di un derivato dell'1alfa-idrossivitamina d per la preparazione di un medicamento per il trattamento dell' iperparatiroidismo
EP0331620A3 (en)	1990-05-23	Agent for the treatment of parkinson's disease
FI890072A7 (fi)	1989-07-09	Menetelmä farmaseuttisesti käyttökelpoisten isokinoliinijohdannaisten valmistamiseksi
FI895417A0 (fi)	1989-11-14	Menetelmä uusien terapeuttisesti käyttökelpoisten 2'-halometylideeninukleosidien valmistamiseksi
FR2646925B1 (fr)	1992-03-20	Sonar d'evitement d'objets sous-marins sub-surface
LV5765B4 (lv)	1997-06-20	(S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
FR2609391B1 (fr)	1991-02-15	Preparations pharmaceutiques sous forme de suppositoires bioadhesifs
KR900020251U (ko)	1990-12-13	차체의 리어덱 구조물
EP0389110A3 (en)	1990-12-19	Process for the preparation of 2'-deoxy-5-trifluoromethyl-beta-uridine
FI900145L (fi)	1990-01-11	Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi